Libevitug Approved in China as First-in-Class Hepatitis D Treatment

2026-01-27 - 08:51

BEIJING, Jan. 27, 2026 /PRNewswire/ — Huahui Health announced that China’s National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus (HBV) and HDV